UNSPSC 51282924: Ibafloxacin

This classification denotes a quinolone antibiotic with the molecular formula C15H14FNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53VPK9R0T5, chemically known as 9-fluoro-6,7-dihydro-5,8-dimethyl-1-oxo-1h,5h-benzo(ij)quinolizine-2-carboxylic acid but generally known as ibafloxacin, which bears US NIH Compound Identifier 71186. European Medicines Agency schedules Ibafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08091MIG.

UNSPSC 51282924 Ibafloxacin is a Commodity code for a specific antibiotic pharmaceutical product, though recent state and local contracting activity under this code shows minimal relevance to ibafloxacin itself. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets, and Seminole County, Florida issued an IFB for Naloxone and Safe Drug Deactivation Systems. Both opportunities reflect state and local health agencies sourcing pharmaceuticals and medical supplies through competitive bidding, cooperative purchasing vehicles, and warehouse distribution models, but neither involves ibafloxacin procurement.

Activity under this code appears limited; recent state and local opportunities posted under UNSPSC 51282924 do not represent actual ibafloxacin buying. The Illinois Department of Public Health and Seminole County, Florida are the jurisdictions appearing in the recent opportunity record, suggesting health departments and county public health offices as the primary issuing bodies when antibiotic pharmaceuticals are sourced. Geographic coverage spans at least the Midwest (Illinois) and Southeast (Florida) regions. The Illinois contract closed on an IFB basis with response due September 11, 2026, and Seminole County's IFB for naloxone and deactivation systems carried a July 26, 2023 deadline. Firms pursuing this code should verify that current solicitations actually target ibafloxacin rather than broader antibiotic or pharmaceutical categories, as the recent posting record suggests potential misalignment between the UNSPSC code and the products state and local buyers are currently requesting.